Previsioni di mercato delle terapie per il cancro al seno nell\'Asia del Pacifico fino al 2030 - Analisi regionale - per terapia farmacologica [terapia farmacologica mirata (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab e altre terapie farmacologiche target), terapia farmacologica ormonale (modulatori selettivi del recettore degli estrogeni, inibitori dell\'aromatasi e downregolatori selettivi del recettore degli estrogeni), chemioterapia e immunoterapia/terapia biologica], tipo di cancro al seno (recettore ormonale, HER2+ e cancro al seno triplo negativo) e canale di distribuzione (farmacie ospedaliere, parafarmacie e farmacie al dettaglio e farmacie online )
Il lancio di numerosi programmi di diagnostica e screening alimenta il mercato terapeutico del cancro al seno nell\'Asia del Pacifico.
I progressi nella medicina personalizzata, nell\'immunoterapia, nella Si prevede che terapie combinate, sistemi di somministrazione di farmaci, biopsie liquide, intelligenza artificiale e approcci incentrati sul paziente daranno forma al futuro del trattamento del cancro al seno. Queste tendenze mirano a migliorare i risultati del trattamento, ridurre gli effetti collaterali e migliorare la qualità della vita complessiva delle pazienti affette da cancro al seno.
La rilevazione precoce della malattia svolge un ruolo importante nel migliorare gli esiti dei pazienti e i tassi di sopravvivenza. Varie organizzazioni e operatori sanitari stanno implementando programmi di screening per individuare il cancro al seno in una fase iniziale quando è più curabile. Nel febbraio 2013 l’Organizzazione Mondiale della Sanità ha pubblicato un nuovo quadro di iniziativa globale sul cancro al seno che funge da piano per raggiungere l’obiettivo di salvare 2,5 milioni di persone dal cancro al seno entro il 2040. Per raggiungere questo obiettivo, il nuovo quadro, presentato in vista della Giornata mondiale contro il cancro campagna, esorta le nazioni a seguire i tre pilastri della promozione della salute per la diagnosi precoce, la diagnosi tempestiva e la gestione approfondita del cancro al seno. Questi programmi spesso includono mammografia, esami clinici del seno ed autoesame del seno per identificare eventuali anomalie o segni di cancro al seno. L’implementazione di questi programmi ha aumentato la consapevolezza e la diagnosi precoce dei casi di cancro al seno, con conseguente maggiore domanda di terapie efficaci.
Inoltre, in tutto il mondo si sono osservati molti progressi nelle tecnologie diagnostiche. La Biblioteca Nazionale di Medicina afferma che la diagnosi precoce e la diagnosi precisa sono essenziali per migliorare la prognosi. La valutazione del cancro al seno si avvale spesso di modalità di imaging radiografico come la mammografia digitale (DM), la tomosintesi digitale del seno (DBT), la risonanza magnetica (MRI), gli ultrasuoni (US) e le procedure di medicina nucleare. L’istopatologia (HP) è il gold standard per determinare la presenza di cancro. Inoltre, l’utilizzo della tecnologia dell’intelligenza artificiale (AI) per rappresentare quantitativamente le immagini mediche ha un potenziale significativo per migliorare la segmentazione, la diagnosi e la prognosi del cancro al seno. Queste tecnologie aiutano gli operatori sanitari a identificare l’estensione e le caratteristiche del tumore, consentendo loro di sviluppare piani di trattamento personalizzati. Pertanto, il lancio di programmi diagnostici e di screening, insieme ai progressi nelle tecnologie diagnostiche, contribuisce alla crescita del mercato delle terapie per il cancro al seno nell’Asia del Pacifico.
Panoramica del mercato delle terapie per il cancro al seno nell\'Asia del Pacifico
Il mercato delle terapie per il cancro al seno nell\'Asia del Pacifico è segmentato in Cina, Giappone, India, Corea del Sud, Australia e nel resto dell\'Asia del Pacifico. La crescita del mercato è attribuita a fattori tra cui il crescente peso dei tumori al seno tra le donne, abbinato ai progressi nella medicina personalizzata, nell’immunoterapia, nelle terapie combinate e nei sistemi di somministrazione dei farmaci.
Si prevede che il mercato delle terapie per il cancro al seno in Cina assisterà a una crescita sostanziale nei prossimi anni, a causa della crescente prevalenza del cancro al seno, dell\'aumento dell\'invecchiamento della popolazione, dei cambiamenti dello stile di vita e di altri fattori. Secondo le statistiche del CDC pubblicate il 14 aprile 2023, la Cina ha rappresentato il 24% dei casi con nuove diagnosi e il 30% dei decessi correlati al cancro a livello globale nel 2020. Negli ultimi tre decenni, l’incidenza standardizzata del cancro al seno per età è salita da 17,07 per 100.000 nel 1990 a 35,61 per 100.000 nel 2019. I progressi nelle opzioni di trattamento hanno svolto un ruolo cruciale nel guidare la domanda di terapie per il cancro al seno in Cina.
Inoltre, in Giappone una donna su 10 prima o poi contrarrà il cancro al seno. La campagna del nastro rosa di ottobre e altre iniziative hanno aumentato la consapevolezza sulla malattia tra i giapponesi, compresa l’importanza degli autocontrolli e di altri metodi di diagnosi precoce che, se utilizzati, aumentano il tasso di sopravvivenza oltre il 90%. L’identificazione delle variabili di rischio tipiche, tuttavia, tarda. Pertanto, si prevede che il mercato delle terapie per il cancro al seno in Giappone crescerà in modo significativo a causa dell’invecchiamento della popolazione, delle opzioni terapeutiche, delle iniziative e delle politiche governative, dell’elevata spesa sanitaria, della crescente consapevolezza e dei progressi tecnologici.
Entrate e previsioni del mercato delle terapie per il cancro al seno nell\'Asia del Pacifico fino al 2030 (milioni di dollari)
Segmentazione del mercato delle terapie per il cancro al seno nell\'Asia del Pacifico
Il mercato delle terapie per il cancro al seno nell\'Asia del Pacifico è segmentato in base alla terapia farmacologica, al tipo di cancro al seno e al canale di distribuzione.
Basato sulla terapia farmacologica, il mercato delle terapie per il cancro al seno nell\'Asia del Pacifico è segmentato in terapia farmacologica mirata, terapia farmacologica ormonale, chemioterapia e immunoterapia/terapia biologica. Il segmento della terapia farmacologica mirata ha detenuto una quota maggiore nel 2022. Il segmento della terapia farmacologica mirata ha detenuto una quota maggiore nel 2022. Il segmento della terapia farmacologica mirata è ulteriormente suddiviso in abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab e altre terapie farmacologiche target. Inoltre, il segmento della terapia farmacologica ormonale è classificato in modulatori selettivi dei recettori degli estrogeni, inibitori dell\'aromatasi e downregolatori selettivi dei recettori degli estrogeni.
In termini di tipo di cancro al seno, il mercato delle terapie per il cancro al seno nell\'Asia del Pacifico è segmentato in recettori ormonali, HER2+ e cancro al seno triplo negativo. Il segmento dei recettori ormonali ha detenuto una quota maggiore nel 2022.
In base al canale di distribuzione, il mercato delle terapie per il cancro al seno nell\'Asia del Pacifico è segmentato in farmacie ospedaliere, farmacie e farmacie al dettaglio e farmacie online. Il segmento delle farmacie ospedaliere ha detenuto una quota maggiore nel 2022.
In base al paese, il mercato delle terapie per il cancro al seno nell\'Asia del Pacifico è classificato in Australia, Cina, India, Giappone, Corea del Sud e resto dell\'Asia del Pacifico. La Cina ha dominato il mercato delle terapie per il cancro al seno nell\'Asia del Pacifico nel 2022.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, e Amgen Inc e Amgen Inc sono alcune delle aziende leader che operano nel mercato delle terapie per il cancro al seno dell\'Asia del Pacifico.
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Breast Cancer Therapeutics Market - Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market - Asia Pacific Market Analysis
5.1 Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy
6.1 Overview
6.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type
7.1 Overview
7.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Breast Cancer Therapeutics Market -Country Analysis
9.1 Asia Pacific Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 Asia Pacific Breast Cancer Therapeutics Market, Breakdown, by Country- Revenue (2022) (US$ Million)
9.1.3 Asia Pacific Breast Cancer Therapeutics Market, by Countries, 2022 and 2030 (%)
9.1.3.1 China
9.1.3.1.1 China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 China: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 China: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 China: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 China: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 China: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Japan
9.1.3.2.1 Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Japan: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Japan: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Japan: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Japan: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Japan: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 India
9.1.3.3.1 India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 India: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 India: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 India: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 India: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 India: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.4 Australia
9.1.3.4.1 Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.2 Australia: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.1 Australia: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.2 Australia: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.3 Australia: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.4.4 Australia: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.5 South Korea
9.1.3.5.1 South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.5.2 South Korea: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.1 South Korea: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.2 South Korea: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.3 South Korea: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.5.4 South Korea: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.6 Rest of Asia Pacific
9.1.3.6.1 Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.6.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.1 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.3 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.6.4 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. Asia Pacific Breast Cancer Therapeutics Market Segmentation
Table 2. Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 3. Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 4. China Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 5. China Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 6. China Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 7. China Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. China Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 9. Japan Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 10. Japan Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 11. Japan Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 12. Japan Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Japan Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. India Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 15. India Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 16. India Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 17. India Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. India Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 19. Australia Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 20. Australia Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 21. Australia Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 22. Australia Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 23. Australia Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 24. South Korea Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 25. South Korea Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 26. South Korea Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 27. South Korea Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 28. South Korea Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of Asia Pacific Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Asia Pacific Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 33. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 34. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 35. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 36. Glossary of Terms, Breast Cancer Therapeutics Market
List of Figures
Figure 1. Asia Pacific Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. Asia Pacific Breast Cancer Therapeutics Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Asia Pacific Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. Asia Pacific Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Growth Strategies in Breast Cancer Therapeutics Market
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Teva Pharmaceutical Industries Ltd
9. Amgen Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific breast cancer therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution